| Last Name | First Name | Country | Abstract Title |
Almeida
| Claudia
| Portugal
| ENDOSOMAL TRAFFICKING DEFECTS IN AGING AND ALZHEIMER’S DISEASE
|
| Ashe | Karen
| USA
| REPAIRING SYNAPTIC
TRANSMISSION IN TAUOPATHIES BY TARGETING CASPASE-2
|
| Attems | Johannes
| UK
| THE ROLE OF PYROGLUATMYLATED AMYLOID- Β IN THE PATHOGENESIS AND DIAGNOSIS OF ALZHEIMER'S DISEASE |
Barthet
| Gael
| France
| PRESENILIN-MEDIATED
CLEAVAGE OF APP REGULATES SYNAPTOTAGMIN-7 AND PRESYNAPTIC PLASTICITY
|
Bezard
| Erwan | France | PRIMATE-SPECIFIC SUSCEPTIBILITY TO NEURODEGENERATION AND SYNUCLEINOPATHY INDUCED BY PATIENT-DERIVED a-SYNUCLEIN EXTRACTS
|
| Bezprozvanny | Ilya | USA | CALCIUM SIGNALING AND SYNAPTIC LOSS IN ALZHEIMER'S DISEASE |
| Blennow | Kaj | Sweden | THE EXPANDED AD FLUID BIOMARKER TOOLBOX - PERFORMANCE FOR DIAGNOSTICS, THERAPY MONITORING AND SCREENING |
| Brooks | David | UK | IMAGING THE TEMPORAL AND SPATIAL INTER-RELATIONSHIPS OF PATHOLOGY WITH PET IN ESTABLISHED AND PRODROMAL ALZHEIMER'S AND PARKINSON'S DISEASE |
| Brundin | Patrik | USA | NOVEL THERAPEUTIC TARGETS FOR PARKINSON'S DISEASE |
| Bu | Goujun | USA | EFFECTS
OF PERIPHERAL APOE ON CNS FUNCTIONS AND AD PATHOGENESIS
|
| Buee | Luc | France | IMPROVING TAU IMMUNOTHERAPY BY ENGINEERING NEW TOOLS: FROM IGGS TO VHHS |
| Checler | Frédéric | France | FUNCTIONAL PRESENILINS-PINK1 INTERPLAY |
| Chiba-Falek | Ornit | USA | THE TALE OF SNCA IN SYNUCLEINOPATHIES: AN INTERPLAY OF GENE DEREGULATION, AGING, AND THE NUCLEUS |
| Cleveland | Don | USA | GENE SILENCING THERAPY IN AD AND PD |
Coelho
| Miguel
| Portugal
| SUPPORTIVE
CARE IN PARKINSON´S DISEASE
|
| Cudkowics | Merit | USA | ACCELERATING THERAPY DEVELOPMENT: LESSONS FROM NEURONEXT PHASE II NETWORK AND AMYOTROPHIC LATERAL SCLEROSIS |
Cuello
| Claudio | Canada
| POTENTIAL TRANSLATIONAL VALUE OF EXPERIMENTAL
THERAPEUTICS IN AD TRANSGENIC MODELS
|
Leonzino
| Marianna
| USA
| LIPID DYNAMICS IN THE ENDOCYTIC PATHWAY AND PARKINSON’S DISEASE GENES
|
| De Strooper | Bart | Belgium | THE VARIOUS CELLULAR RESPONSES IN ALZHEIMER'S DISEASE |
| Diamond | Marc | USA | BIOCHEMISTRY AND STRUCTURAL BIOLOGY OF TAU PRIONS: IMPACT ON DIAGNOSIS AND THERAPY |
Di Luca
| Monica | Italy
| TARGETING ADAM10
SYNAPTIC TRAFFICKING AS THERAPEUTIC TARGET FOR AD
|
Duff
| Karen
| USA
| PROPAGATION OF TAUOPATHY: MECHANISMS AND THERAPEUTIC OPPORTUNITIES
|
Ferreira
| Joaquim | Portugal
| BOTTLENECKS IN DRUG
DEVELOPMENT PROGRAMS IN PARKINSON’S DISEASE
|
|
| Frenkel | Dan | Israel | TARGETING PATHOLOGICAL PATHWAYS IN GLIA IN AD: WHEN FRIENDS BECOME FOES |
| Frisoni | Giovanni B. | Switzerland | THE GUT MICROBIOTA IN AD: PRECLINICAL AND CLINICAL EVIDENCE OF AN ASSOCIATION |
Frykman
| Susanne
| Sweden
| SPECIES AND
DEVELOPMENTAL DIFFERENCES IN PROCESSING OF THE AMYLOID PRECURSOR PROTEIN
|
| Futerman | Anthony | Israel | LYSOSOMAL STORAGE DISEASES AND PD |
| Galvin | James | USA | CAN DEMENTIA BE PREVENTED: LESSONS LEARNED AND APPLIED IN RESEARCH AND CLINICAL PRACTICE |
Gerwert
| Klaus
| Germany
| A STRUCTURE-BASED AMYLOID BLOOD BIOMARKER FOR PRECLINICAL ALZHEIMER`S IDENTIFICATION AND THERAPY RESPONSE MONITORING
|
| Geula | Changiz | USA | ELDERLY WITH SUPERIOR MEMORY AND THE FULL RANGE OF ALZHEIMER PATHOLOGY: RESILIENCE AND NEUROPROTECTION |
Giacobini
| Ezio
| Switzerland
| REVISITING THE CHOLINERGIC HYPOTHESIS AND DESIGNING
NEW CHOLINERGIC APPROACHES
|
| Giladi | Nir | Israel
| PERSONALIZED APPROACH TO TREATING PATIENTS WITH PARKINSON, THE ROLE OF GENETIC BACKGROUND |
| Goate | Alison | USA | BIOLOGICAL PATHWAYS IMPLICATED IN ALZHEIMER'S DISEASE RISK THROUGH GENETIC STUDIES |
Gold
| Gabriel
| Switzerland
| VASCULAR COGNITIVE IMPAIRMENT : SMALL LESIONS AND THEIR
CONSEQUENCES
|
| Golde | Todd | USA | A PRECLINICAL ROAD MAP TO DEVELOP COMBINATORIAL THERAPIES THAT CAN RESCUE BRIAN ORGAN FAILURE IN NEURODEGENERATIVE DISEASE |
| Growdon | John | USA | MOLECULAR PET SCANS REVEAL THE BASIS OF DEMENTIA IN PARKINSON DISEASE |
Haass
| Christian | Germany
| TREM2 – FROM BASIC MECHANISMS TO HUMAN PATIENTS
|
Hardy
| John
| UK
| GENOMICS AND NEURODEGENERATION
|
Halliday
| Glenda | Australia
| ROLE OF
ALPHA-SYNUCLEIN AND LESSONS LEARNED FROM THE BRAIN
|
|
| Heneka | Michael | Germany | NLRP3 MEDIATED INNATE IMMUNITY IN ALZHEIMER'S DISEASE |
| Higuchi | Makato | Japan | IN-VIVO IMAGING OF TAU AND ALPHA-SYNUCLEIN PATHOLOGIES FROM MICROSCOPIC TO MACROSCOPIC SCALES |
| Holtzman | David | USA | UNDERSTANDING THE
EFFECT OF APOE ON TAU-MEDIATED NEURODEGENERATION |
| Hyman | Bradley | USA | MOLECULAR MECHANISMS OF PROGRESSION IN ALZHEIMER DISEASE |
| Inestrosa | Nibaldo C. | Chile | WNT SIGNALING HAS A KEY ROLE IN ALZHEIMER´S DISEASE: REGULATION OF APP PROCESSING AND TAU PHOSPHORYLATION |
| Isacson | Ole | USA | LIPID AND PROTEIN INTERACTIONS CAUSING NEURODEGENERATIVE DISEASES |
| Iwatsubo | Takeshi | Japan | TOWARD DISEASE-MODIFYING THERAPY FOR ALZHEIMER'S DISEASE: JAPANESE ADNI AND A4 STUDIES |
Johnson
| Keith
| USA
| MOLECULAR PET BIOMARKERS OF ALZHEIMER PATHOLOGY:
FOCUS ON PRECLINICAL DISEASE
|
| Jeon | Beomseok
| Korea | PERIPHERAL TISSUE BIOMARKER OF PARKINSON'S DISEASE |
| Koo | Edward | USA | SYNAPTIC INJURY IN ALZHEIMER DISEASE: Ab AND APP-DEPENDENT MECHANISMS
|
| Korczyn | Amos D. | Israel | THE NEGLECTED AVENUES IN PREVENTING AD |
Kulisevsky
| Jaime
| Spain
| HALLUCINATIONS IN PD: NEUROANATOMICAL CORRELATES
|
Labrie
| Viviane
| USA
| THE VERMIFORM APPENDIX CONTRIBUTES TO THE DEVELOPMENT
OF PARKINSON’S DISEASE
|
| Laferla | Frank | USA | DEVELOPING THE NEXT GENERATION OF ALZHEIMERS ANIMAL MODELS.
|
| Lazarov | Orly | USA | MOLECULAR MECHANISMS UNDERLYING THE DEVELOPMENT
OF SPORADIC ALZHEIMER’S DISEASE
|
| Lee | Virginia | USA
| TRANSMISSION OF MISFOLDED PROTEINS IN NEURODEGENERATIVE DISORDERS: A COMMON MECHANISM OF DISEASE PROGRESSION
|
| Lee | Seung-Jae | Korea | MECHANISM OF ALPHA-SYNUCLEIN AGGREGATE PROPAGATION |
| Lehericy | Stephane | France | STATE-OF-THE-ART AND CURRENT CHALLENGES IN MRI
BIOMARKERS IN PARKINSONISM |
| Lemere | Cynthia | USA | FOCUSED ULTRASOUND IMPROVES THERAPEUTIC EFFICACY OF ANTI-PYROGLU3 ABETA IMMUNOTHERAPY IN APP/PS1 MICE |
| Lipton | Stuart | USA | SOLUBLE AGGREGATES OF α-SYNUCLEIN/ANTIBODY COMPLEXES ACTIVATE THE NLRP3 INFLAMMASOME IN HUMAN INDUCED PLURIPOTENT STEM CELL (hiPSC)-DERIVED MICROGLIA
|
Mandelkow
| Eva
| Germany
| REVERSAL OF SYNAPTOTOXICITY IN MOUSE MODELS OF
NEURODEGENERATION BY BLOCKING ADENOSINE A1 RECEPTORS
|
Mandelkow
| Eckhard
| Germany
| TAU IN NEURONAL COMPARTMENTS: SORTING, MISSORTING, TRANSMISSION, AND CONSEQUENCES FOR SYNAPTIC FUNCTION
|
| Marek | Ken | USA | HOW CAN BIOMARKERS IN PARKINSON DISEASE INFORM CLINICAL TRIALS – THE PPMI STUDY |
| Masters | Colin | Australia | A QUANTITATIVE APPROACH TO PRIMARY PREVENTION OF ALZHEIMER'S DISEASE: PROGRESS IN BLOOD-BASED SCREENS AND OTHER METHODS TO DETECT PERSONS AT RISK. |
| Michaelson | Daniel M. | Israel | COMPLIMENTARY APPROACHES TO ALZHEIMER THERAPY BASED ON REVERSAL OF THE HYPOLIPIDATION OF APOE4 AND ON ANTI-APOE4 IMMUNOTHERAPY |
| Mirelman | Anat | Israel | MOTOR –COGNITIVE INTERACTIONS IN NEURODEGENERATION |
| Mook-Jung | Inhee | Korea
| THERAPEUTIC
APPROACHES TO REDUCE PATHOLOGICAL TAU BURDEN IN THE BRAINS OF ALZHEIMER'S
DISEASE MOUSE MODEL
|
Morais
| Vanessa
| Portugal
| PARKINSON’S DISEASE: THE IMPORTANCE OF MITOCHONDRIA FOR BRAIN
HOMEOSTASIS
|
|
| Morgan | Dave | USA | MARKERS OF INFLAMMATION IN ALZHEIMER'S DISEASE |
| Morizane | Asuka | Japan | STEM CELL THERAPY FOR PARKINSON'S DISESE PROGRESSING TO THE CLINIC |
| Morris | John C
| USA | RACIAL SIMILARITIES AND DIFFERENCES IN ALZHEIMER BIOMARKERS |
| Mucke | Lennart | USA | PROTEINOPATHIES OF THE AGING BRAIN: FROM NETWORK DYSFUNCTION TO NEURODEGENERATION |
| Multhaup | Gerhard | Canada | MOLECULAR DISSECTION OF AMYLOID CLEARANCE PATHWAYS: TOXIC VERSUS NON-TOXIC ABETA |
Nielsen
| Henrietta
| Sweden
| AN EMERGING RELATIONSHIP BETWEEN APOE AND
ALPHA-SYNUCLEIN IN THE CONTEXT OF AD
|
| Nordberg | Agneta | Sweden | THE COMPLEXIITY OF TAU PET IMAGING IN EARLY DIAGNOSIS OF NEURODEGENERATIVE PROTEINOPATHIES |
| Outeiro | Tiago | Germany | THE EFFECT OF ALPHA-SYNUCLEIN ON TRANSCRIPTION: INSIGHTS INTO SYNUCLEINOPATHIES |
| Petersen | Ronald | USA | PROGRESS TOWARD EVALUATING THE NIA-AA ALZHEIMER'S FRAMEWORK |
| Polymenidou | Magdalini | Switzerland | PATHOLOGICAL TDP-43 ASSEMBLIES AND DISEASE HETEROGENEITY |
| Prado | Marco | Canada | CHOLINERGIC CONTROL OF PATHOLOGY AND COGNITION IN ALZHEIMER'S DISEASE |
| Ranum | Laura | USA | REPEAT ASSOCIATED NON-ATG (RAN) TRANSLATION IN C9ORF72 ALS/FTD: MECHANISTIC INSIGHTS AND THERAPEUTIC OPPORTUNITIES |
| Rektorova | Irena | Czech Republic | COMBINING IMAGING AND CLINICAL BIOMARKERS FOR EARLY DIAGNOSIS OF LEWY BODY DISEASES |
| Schapira | Antony | UK | NOVEL THERAPEUTIC STRATEGIES FOR DISEASE MODIFICATION IN PARKINSON DISEASE' |
| Scheltens | Philip | The Netherlands | TAKING ALZHEIMER DIAGNOSIS TO THE NEXT LEVEL |
| Schlossmacher | Michael | Canada | ALPHA-SYNUCLEIN AND LRRK2 MODULATE THE OUTCOME OF INFECTIONS IN BACTERIAL SEPSIS AND VIRAL ENCEPHALITIS
|
| Schmidt | Reinhold | Austria | MRI-DETECTED
IRON DEPOSITION IN NORMAL AGING AND DEMENTIA
|
|
| Schmitz | Taylor | Canada
| PROTEOPATHY AND ASTROGLIAL REACTIVITY DRIVE CHOLINERGIC
NEURODEGENERATION IN PRECLINICAL ALZHEIMER’S DISEASE
|
| Schwartz | Michal | Israel | HARNESSING THE SYSTEMIC AND THE BRAIN'S SPECIFIC IMMUNE SYSTEM TO COMBAT ALZHEIMER'S DISEASE |
| Segal | Menahem | Israel | CALCIUM STORES AND ALZHEIMER'S DISEASE |
| Shen | Jie | USA | PRESENILIN AND APP IN FAMILIAL ALZHEIMER’S DISEASE
|
| Snyder | Peter | USA | NON-AMYLOID RETINAL BIOMARKERS FOR PRECLINICAL AD SCREENING |
| Solomon | Alina
| Finland | EFFECTS OF FORTASYN CONNECT IN PRODROMAL ALZHEIMER'S DISEASE: NEW RESULTS FROM THE LIPIDIDIET TRIAL
|
| Solomon | Beka | Israel | MOBILIZATION OF ENDOGENOUS MICROGLIA-LIKE HEMATOPOIETIC STEM CELLS AS A THERAPEUTIC STRATEGY FOR TREATMENT OF ALZHEIMER'S DISEASE |
| Soreq | Hermona | Israel | CIRCULAR RNAS CONTROL OXIDATIVE STRESS RESPONSES IN THE PARKINSON BRAIN |
| Sperling | Reisa | USA | THE NEXT GENERATION OF ALZHEIMER'S DISEASE PREVENTION TRIALS |
| Spillantini | Maria Grazia | UK | CROSS-TALK BETWEEN NEURONS AND GLIAL CELLS IN
NEURODEGENERATIVE DISEASES WITH TAU AGGREGATION
|
| St. George-Hyslop | Peter | Canada | TREM2 AND CD33
SIGNALLING IN MICROGLIAL DYSFUNCTION IN AD |
Suh
| Yoo-Hun | Korea
| STEM CELL TRANSPLANTATION AT THE EARLY STAGES OF THE DISEASE IMPROVES LEARNING ,MEMORY AND BRAIN LESIONS IN ALZHEIMER'S DISEASE MICE
|
| Trojanowski | John Q. | USA | TAU STRAINS AND SPREADING IN PURE TAUOPATHIES AND ALZHEIMER’S DISEASE
|
| Tsai | Li-Huei | USA | LEVERAGING
BRAIN RHYTHMS AS A THERAPEUTIC INTERVENTION FOR ALZHEIMER’S DISEASE
|
| Van Broeckhoven | Christine | Belgium | A
PLETHORA OF GENETIC VARIATIONS IN CAUSAL AND RISK GENES ARE CONTRIBUTING TO
EARLY-ONSET DEMENTIA
|
|
| Vassar | Robert | USA |
BACE1: THE BETA-SECRETASE ENZYME IN HEALTH AND ALZHEIMER'S DISEASE |
| Weiner | Michael | USA | MEASURING BRAIN, CEREBROSPINAL FLUID, AND BLOOD FOR AMYLOID AND TAU TO DIAGNOSE ALZHEIMER'S DISEASE; LESSONS FROM THE ALZHEIMER'S DISEASE NEUROIMAGING INTITIATIVE |
| Weiner | Howard | USA | CENTRAL AND PERIPHERAL INNATE IMMUNE THERAPEUTIC MECHANISMS IN ALZHEIMER'S DISEASE AND THE ROLE OF THE MICROBIOME
|
| Wilcock | Donna | USA | THERAPEUTIC TARGETING OF TREM2 FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| Wong | Philip | USA | TARGETING TDP-43, A GUARDIAN OF THE TRANSCRIPTOME, FOR NEURODEGENERATIVE DISEASE |
| Wszolek | Zbigniew | USA | PERRY SYNDROME – PARKINSONIAN CONDITION WITH TDP-43 PATHOLOGY |
| Xu | Huaxi | USA | TREM2 MEDIATES MICROGLIAL FUNCTION IN RESPONSE TO BETA-AMYOID |
| Yue | Zhenyu | USA | REGULATION OF a-SYNUCLEIN TRANSMISSION BY AUTOPHAGY IN CNS |
| Zhou | Jiawei | China | BALANCING THE INNATE IMMUNE SYSTEM IN THE BRAIN: INTERPLAY BETWEEN NG2 GLIAL AND MICROGLIAL CELLS |
| Nation | Daniel
| USA | BLOOD–BRAIN BARRIER BREAKDOWN IS AN EARLY BIOMARKER OF HUMAN COGNITIVE DYSFUNCTION
|
